中西药治疗脉络膜新生血管性疾病疗效观察

Clinical Observation on Integrated Traditional and Western Medicine in Treating Choroidal Neovascularization

目的:观察黄斑方联合抗氧化剂治疗脉络膜新生血管性疾病(CNV)的临床疗效。方法:对2004年至2015年就诊的31例(35只眼)视力、眼底彩照进行回顾性分析,并将视力与眼底形态学改变进行相关分析。结果:视力平均值治疗前与治疗后3、6、12个月时比较差异有统计学意义(P<0.05);治疗后3个月时与治疗后6个月时比较,差异也有统计学意义(P<0.05);治疗后6个月时与治疗后12个月时比较,差异无统计学意义(P>0.05)。CNV总面积平均值治疗前与治疗后3个月时比较,差异无统计学意义(P>0.05);治疗前与治疗后6、12月时比较,差异有统计学意义(P<0.05);治疗后3个月时与治疗后6、12个月时比较,差异有统计学意义(P<0.05);治疗后6个月时与治疗后12个月时比较,差异有统计学意义(P<0.05)。治疗后12个月时视力提高19只眼(54.3%),视力稳定14只眼(40.0%),视力下降2只眼(5.7%)。CNV最大病灶面积与视力在治疗前无相关性,在治疗后3、6、12个月时均呈负相关。结论:黄斑方联合抗氧化剂治疗脉络膜新生血管性疾病能有效缩小病灶及减少荧光素渗漏。

Objective： To observe clinical effects of macular lutea prescription combined with antioxidant in treating choroidal neovascularization （CNV）. Methods： The visions and fundus photograph of 31 patients （35 eyes） were retrospectively analyzed, and the correlation between vision and the related morphological changes of fimdi were analyzed. Results： The difference had statistical meaning in the comparisons of average eyesight between before treating, and in three months, six months and 12 months after treating （P〈0.05）; the difference presented statistical meaning in the comparison in three months and six months after treating （P〈0.05）; the difference had no statistical meaning in the comparison between in six months and 12 months after treating （P〉0.05）. The difference had no statistical meaning in the comparisons of average value of CNV total area between before treating and in three months after treating （P〉0.05）; the difference showed statistical meaning in the comparison between before treating, in six and 12 months after treating （P〈0.05）; and the difference had statistical meaning in the comparison between in three months, six months and 12 months after treating （P〈0.05）; and the difference showed statistical meaning in the comparison between in six months and 12 months after treating （P〈0.05）. In 12 months after treating, the eyesight of 19 eyes were improved （54.3%）, 14 eyes with stable eyesight （40.0%）, two eyes with impaired eyesight （5.7%）. The largest focus area of CNV showed no relativity to the vision before treating, negatively related to the vision in three, six and 12 months after treating. Conclusion： Macular lutea prescription combined with antioxidant in treating CNV could effectively reduce focus and fluoresce in leakage effectively.